Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MYGN
stocks logo

MYGN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
205.14M
-3.83%
-0.011
-118.97%
207.50M
-1.47%
-0.015
-149.57%
Estimates Revision
The market is revising Downward the revenue expectations for Myriad Genetics, Inc. (MYGN) for FY2025, with the revenue forecasts being adjusted by -0.04% over the past three months. During the same period, the stock price has changed by 10.89%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.04%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-33.2%
In Past 3 Month
Stock Price
Go Up
up Image
+10.89%
In Past 3 Month
Wall Street analysts forecast MYGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MYGN is 8.50 USD with a low forecast of 8.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast MYGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MYGN is 8.50 USD with a low forecast of 8.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 7.330
sliders
Low
8.00
Averages
8.50
High
9.00
Current: 7.330
sliders
Low
8.00
Averages
8.50
High
9.00
Piper Sandler
Overweight
downgrade
$9
2025-11-11
Reason
Piper Sandler
Price Target
$9
2025-11-11
downgrade
Overweight
Reason
Piper Sandler lowered the firm's price target on Myriad Genetics to $8.50 from $9 and keeps an Overweight rating on the shares. The firm cites the company's quarterly results for the price target change.
UBS
Lu Li
Neutral
maintain
$6 -> $8
2025-11-04
Reason
UBS
Lu Li
Price Target
$6 -> $8
2025-11-04
maintain
Neutral
Reason
UBS analyst Lu Li raised the firm's price target on Myriad Genetics to $8 from $6 and keeps a Neutral rating on the shares.
TD Cowen
Hold
maintain
$8 -> $9
2025-11-04
Reason
TD Cowen
Price Target
$8 -> $9
2025-11-04
maintain
Hold
Reason
TD Cowen raised the firm's price target on Myriad Genetics to $9 from $8 and keeps a Hold rating on the shares. The firm said they reported a 3Q result about in line with consensus expectations, with HCT and GeneSight bright spots and Prenatal a bit weak but improving.
Scotiabank
Outperform -> Sector Perform
downgrade
$20 -> $6
2025-05-21
Reason
Scotiabank
Price Target
$20 -> $6
2025-05-21
downgrade
Outperform -> Sector Perform
Reason
BofA
Underperform
downgrade
$9 -> $4
2025-05-20
Reason
BofA
Price Target
$9 -> $4
2025-05-20
downgrade
Underperform
Reason
Scotiabank
Outperform -> Sector Perform
downgrade
$6
2025-05-20
Reason
Scotiabank
Price Target
$6
2025-05-20
downgrade
Outperform -> Sector Perform
Reason
Scotiabank downgraded Myriad Genetics to Sector Perform from Outperform with a $6 price target.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Myriad Genetics Inc (MYGN.O) is 234.19, compared to its 5-year average forward P/E of -15.60. For a more detailed relative valuation and DCF analysis to assess Myriad Genetics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-15.60
Current PE
234.19
Overvalued PE
420.98
Undervalued PE
-452.18

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
38.87
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
124.21
Undervalued EV/EBITDA
-46.47

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.28
Current PS
0.00
Overvalued PS
3.19
Undervalued PS
1.37
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

MYGN News & Events

Events Timeline

(ET)
2025-11-10
08:44:14
Myriad Genetics expands MyRisk test with 15 new clinically actionable genes
select
2025-11-03 (ET)
2025-11-03
17:08:40
Myriad Genetics supports FY25 adjusted EPS forecast of 2c-2c, consensus at 1c
select
2025-11-03
17:07:12
Myriad Genetics announces Q3 adjusted EPS of 0c, below consensus estimate of (1c)
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.5
11-26Yahoo Finance
Market Update: Health Care Stocks Rise in Premarket Trading on Wednesday

  • Health Care Stocks Performance: Health care stocks were showing an upward trend in premarket trading on Wednesday.

  • Sector Focus: The movement was particularly noted in the Health Care Select Sector SPDR Fund.

[object Object]
Preview
7.5
11-26Newsfilter
Clairity and Myriad Collaborate to Enhance Breast Cancer Risk Assessment
  • Collaborative Innovation: Clairity, Myriad Genetics, and MagView have partnered to launch a new platform aimed at enhancing the identification of high-risk women for breast cancer by integrating genotype and phenotype data, which is expected to significantly improve breast cancer screening processes.
  • Technology Integration: The new platform combines Myriad's MyRisk hereditary cancer test with Clairity Breast's AI-powered risk assessment, providing a more comprehensive view of risk that enables clinicians to make earlier, personalized interventions, thereby reducing breast cancer mortality rates.
  • Market Impact: MagView's Luminary Risk software is already utilized in over 2,500 healthcare facilities across the U.S., and the integration of this new technology is anticipated to further enhance workflow efficiency and patient experience, driving personalized breast health management.
  • Strategic Goals: This collaboration not only addresses a critical gap in breast cancer risk assessment but also aims to reduce administrative burdens, enabling healthcare institutions to achieve more efficient screening and management in cancer care, aligning with the industry's shift towards preventive care.
[object Object]
Preview
9.5
11-17NASDAQ.COM
What Factors Contributed to Tempus AI Achieving Positive EBITDA in Q3?

  • Tempus AI Financial Performance: Tempus AI reported a positive adjusted EBITDA of $1.5 million in Q3, driven by strong growth in its Genomics and Data Licensing businesses, with significant increases in Oncology and Hereditary testing volumes.

  • Myriad Genetics and Quest Diagnostics: Myriad Genetics achieved an adjusted EBITDA of $10.3 million, supported by a high gross margin and controlled expenses, while Quest Diagnostics improved profitability with expanded margins and ongoing cost-saving initiatives.

  • Stock Performance and Market Position: Tempus AI's shares have increased by 26.7% over the past year, outperforming industry and S&P 500 averages, and the company's stock currently has a forward Price-to-Sales ratio of 8.00X, above the industry average.

  • Emerging Quantum Computing Trends: Quantum computing is rapidly advancing, with major tech companies integrating it into their infrastructure, and investment strategist Kevin Cook identifies key stocks that may lead in this emerging field.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Myriad Genetics Inc (MYGN) stock price today?

The current price of MYGN is 7.33 USD — it has increased 0 % in the last trading day.

arrow icon

What is Myriad Genetics Inc (MYGN)'s business?

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.

arrow icon

What is the price predicton of MYGN Stock?

Wall Street analysts forecast MYGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MYGN is 8.50 USD with a low forecast of 8.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Myriad Genetics Inc (MYGN)'s revenue for the last quarter?

Myriad Genetics Inc revenue for the last quarter amounts to 205.70M USD, decreased -3.56 % YoY.

arrow icon

What is Myriad Genetics Inc (MYGN)'s earnings per share (EPS) for the last quarter?

Myriad Genetics Inc. EPS for the last quarter amounts to -0.29 USD, increased 20.83 % YoY.

arrow icon

What changes have occurred in the market's expectations for Myriad Genetics Inc (MYGN)'s fundamentals?

The market is revising Downward the revenue expectations for Myriad Genetics, Inc. (MYGN) for FY2025, with the revenue forecasts being adjusted by -0.04% over the past three months. During the same period, the stock price has changed by 10.89%.
arrow icon

How many employees does Myriad Genetics Inc (MYGN). have?

Myriad Genetics Inc (MYGN) has 2700 emplpoyees as of December 05 2025.

arrow icon

What is Myriad Genetics Inc (MYGN) market cap?

Today MYGN has the market capitalization of 683.26M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free